Review of Accelerated Cancer Treatment Approvals: A Cross-Sectional Study in China from 2005 to 2021 - Takeaways - MDSpire

Review of Accelerated Cancer Treatment Approvals: A Cross-Sectional Study in China from 2005 to 2021

  • By

  • Yun Tian

  • Xingyu Liu

  • Xingchen Liu

  • Xiaoyong Liu

  • Shuchen Hu

  • Xiaodong Liu

  • Caijun Yang

  • Yu Fang

  • February 16, 2026

  • 0 min

Share

  • 1

    China has the highest global cancer incidence and mortality rates, with 4.57 million new cases and 3 million deaths reported in 2020.

  • 2

    The expedited approval programs in China, initiated in 2005, aim to accelerate patient access to innovative cancer therapies.

  • 3

    China approved 94 new anticancer drugs through expedited programs from 2005 to 2021, reflecting a significant regulatory shift.

  • 4

    The Conditional Approval pathway allows for quicker drug approvals based on less comprehensive data, enhancing access to promising therapies.

  • 5

    The study analyzes the impact of expedited review processes on the speed and clinical value of oncology drugs approved in China.

Original Source(s)

Review of Accelerated Cancer Treatment Approvals: A Cross-Sectional Study in China from 2005 to 2021

  • by Yun Tian, Xingyu Liu, Xingchen Liu, Xiaoyong Liu, Shuchen Hu, Xiaodong Liu, Caijun Yang, Yu Fang

  • February 16, 2026

Related Content

Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives

New Clues in Hodgkin Lymphoma Biology

Transcriptome analysis highlights diagnostic targets and immune evasion pathways

  • May 14, 2026

  • 2 min
Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago

  • by

  • May 25, 2026

  • 9 min